email article We re going to be in a Pinkalicious phase for the next few months. Chris Martin, MD, MSc, of West Virginia University School of Public Health, quoting surprisingly apt advice from the popular children s book series and applying it to potentially choosing one s COVID vaccine. It is sloppy and lazy to lump cladribine and alemtuzumab together. Gavin Giovannoni, MBBCh, PhD, of Queen Mary University of London in England, discussing the issue of some multiple sclerosis drugs possibly attenuating antibody responses to COVID vaccination. I felt immense pain when he died because I knew how close I was [to suicide] when I was at his stage of education. Christopher Veal, a fourth-year medical student at the University of Vermont in Burlington, reflecting on the suicide of a fellow student and his own brush with suicidal ideation.
email article
Most vaccines, including the COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna, generally are safe for people with multiple sclerosis (MS), according to a prominent researcher in the field.
However, some MS disease-modifying treatments (DMTs) may affect COVID vaccine responses, which may be influenced by the timing of the vaccine relative to treatment, said Amit Bar-Or, MD, of the University of Pennsylvania in Philadelphia, at ACTRIMS Forum 2021, the annual meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis.
There isn t a serious question about the COVID vaccines safety in MS patients. These are non-live, inactivated vaccines, he said. The merits of protection from COVID by far outweigh any risk.
Most women stuck with pessary treatment for symptomatic pelvic organ prolapse (POP), according to a long-term study.
In a prospective study of 312 Chinese women with symptomatic POP, 75% continued with pessary treatment either with a ring or Gellhorn pessary 5 years after initial fitting, reported Lan Zhu, MD, of Peking Union Medical College Hospital in Beijing, and colleagues.
Appearing in
Menopause, the journal of the North American Menopause Society (NAMS), the researchers pinpointed certain factors that were tied to a higher chance of women discontinuing pessary treatment.
These included having a vaginal length less then 7.5 cm (OR 2.7, 95% CI 1.3-5.7, P=0.007) and being unable to care for themselves (OR 2.6, 95% CI 1.3-5.1,